Treatment of experimental chronic pulmonary mycoplasmosis

Monica Fonseca-Aten, Ana Maria Rios, Asuncion Mejias, Susana Chavez-Bueno, Kathy Katz, Ana Maria Gomez, Octavio Ramilo, George H. McCracken, R. Doug Hardy

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Mycoplasma pneumoniae infection has been associated with chronic lung disease. Treatment of chronic pulmonary mycoplasmosis has not been well investigated. BALB/c mice were intranasally inoculated once with M. pneumoniae or with sterile media (uninfected controls). Infected mice were treated with telithromycin or placebo daily for 10 days in the chronic phase of disease (18 months after inoculation). Mice (n = 43) were evaluated before therapy and 1 day after completion of telithromycin. Treatment of infected mice with telithromycin at 18 months after infection significantly reduced chronic pulmonary histological inflammation compared with infected mice given placebo; however, this treatment did not improve airway obstruction or airway hyperresponsiveness. Therapy longer than 10 days may be necessary to improve pulmonary function.

Original languageEnglish (US)
Pages (from-to)253-258
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Issue number3
StatePublished - Sep 2006


  • Asthma
  • Chronic infection
  • Mycoplasma pneumoniae
  • Pneumonia
  • Reactive airway disease
  • Telithromycin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of experimental chronic pulmonary mycoplasmosis'. Together they form a unique fingerprint.

Cite this